Dicerna Pharmaceuticals (DRNA) CAPEX/Revenue US GAAP (year values)
2016 2017 2018 2019 2020   LTM ? CAGR 5 years ?
CAPEX/Revenue, % 152.2% 5.84% 5.81% 26.6% 7.15%   6.48%  
Changes by years, y/y, % -464pp -146pp 0pp +21pp -19pp     -59.0%
Compare with other companies

Dicerna Pharmaceuticals. CAPEX/Revenue, %

Dicerna Pharmaceuticals. CAPEX/Revenue, changes, pp

Dicerna Pharmaceuticals (DRNA) CAPEX/Revenue US GAAP (quarter values)
2020Q3 2020Q4 2021Q1 2021Q2 2021Q3   LTM ?
CAPEX/Revenue, % 8.46% 10.4% 7.10% 11.7% 0.03%   6.48%
Changes by years, y/y, % -10pp -4pp +3pp +7pp -8pp    
Changes by quarters, q/q, % +4pp +2pp -3pp +5pp -12pp    

Dicerna Pharmaceuticals. CAPEX/Revenue, %

Dicerna Pharmaceuticals. CAPEX/Revenue, changes, pp

Dicerna Pharmaceuticals. CAPEX/Revenue, changes, pp


Have an idea?
Blogs All blogs wire
Most useful
Most commented
NEWS
Trade Signals
Answers to questions
Books reviews
Corporate blogs
Forums All forums wire
Common
Stocks
Algotrading
Options
Cryptocurrencies
Forex
Brokers rating
Stocks Heat Map
Quotes
Fundamental analysis
Financials
Dividends
My portfolio
All companies
Stocks Calendar
Smartlab Smartlab Values
SiteMap
Ads
Contacts

Rules
Help
Feedback
Moscow Exchange is the source and the owner of marketdata. The users haven't right of further distribution or presentation of any data without written permission of Moscow Exchange, haven't right to create modified information for further public distribution to third parties.